SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76923.00
87.22 (0.11%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
31	Vijaya Diagnostic Centre Ltd.	Q V PT	13,894 Small Cap	1,347 (-0.14%)	80.32	14.52	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
32	Supriya Lifescience Ltd.	Q V+ PT	6,799 Small Cap	833.30 (-1.36%)	32.51	5.68	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
33	Glaxosmithkline Pharmaceuticals Ltd.	Q V PT	43,202 Mid Cap	2,574.05 (0.94%)	41.7	18.92	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
34	Abbott India Ltd.	Q V PT	59,102 Mid Cap	27,892.65 (0.28%)	38.08	12.45	9.96	17.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
35	Kovai Medical Center & Hospital Ltd.	Q V PT	6,411 Small Cap	5,946.75 (1.51%)	26.22	4.86	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
36	Krishna Institute of Medical Sciences Ltd	Q V PT	33,598 Small Cap	791.35 (-1.08%)	128.88	8.55	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
37	Acutaas Chemicals Ltd.	Q V+ PT	27,579 Small Cap	3,121.05 (-7.35%)	69.39	15.81	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
38	Dr. Reddys Laboratories Ltd.	Q V+ PT	96,063 Mid Cap	1,145.50 (-0.47%)	29.81	2.52	12.09	15.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
39	Astrazeneca Pharma India Ltd.	Q V PT	20,420 Small Cap	8,105 (-0.77%)	108.89	23.57	22.84	15.69	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
40	Gujarat Themis Biosyn Ltd.	Q V+ PT	3,930 Small Cap	356.25 (-1.22%)	84.18	13.66	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
41	Windlas Biotech Ltd.	Q V PT	1,769 Small Cap	858.60 (0.18%)	26.62	3.44	16.15	15.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
42	Zydus Lifesciences Ltd.	Q V PT	1,10,523 Mid Cap	1,109 (0.09%)	21.93	4.25	13.52	14.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
43	Innova Captab Ltd.	Q V PT	5,527 Small Cap	966.05 (0.02%)	66.04	6.23	25.90	14.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
44	SMS Pharmaceuticals Ltd.	Q V+ PT	3,662 Small Cap	382.60 (-2.15%)	41.8	4.55	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
45	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,73,509 Large Cap	1,984.40 (0.55%)	41.25	5.67	11.78	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
46	Glenmark Pharmaceuticals Ltd.	Q V+ PT	61,928 Mid Cap	2,199.25 (0.22%)	45.47	5.89	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
47	Kopran Ltd.	Q V PT	975 Small Cap	198.50 (-1.68%)	32.07	2.18	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
48	Indegene Ltd.	Q V+ PT	12,241 Small Cap	510.70 (0.50%)	30.52	3.96	29.44	13.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
49	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,90,832 Large Cap	4,921.50 (-1.90%)	88.21	22.69	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
50	Advanced Enzyme Technologies Ltd.	Q V PT	3,555 Small Cap	315 (-0.77%)	26.97	5.07	9.82	13.51	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
51	Mankind Pharma Ltd.	Q V PT	1,05,357 Mid Cap	2,586.60 (1.39%)	51.71	6.44	13.54	13.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
52	Dr. Lal Pathlabs Ltd.	Q V PT	30,607 Small Cap	1,816.90 (-0.49%)	56.18	11.9	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
53	Anuh Pharma Ltd.	Q V PT	809 Small Cap	80.03 (-0.85%)	19.71	2.3	12.30	12.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
54	KMC Speciality Hospitals (India) Ltd.	Q V PT	2,127 Small Cap	130.45 (0.00%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
55	Procter & Gamble Health Ltd.	Q V+ PT	11,257 Small Cap	6,764 (-0.26%)	34.43	21.46	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
56	Lincoln Pharmaceuticals Ltd.	Q V PT	1,163 Small Cap	581.95 (0.25%)	13.23	1.53	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
57	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	10,638 Small Cap	664.25 (-1.72%)	95.29	4.38	10.00	11.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
58	Sai Life Sciences Ltd.	Q V+ PT	27,347 Small Cap	1,291.45 (0.26%)	80.08	10.9	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
59	Ajanta Pharma Ltd.	Q V+ PT	42,278 Mid Cap	3,358 (-0.77%)	40.04	9.35	13.54	10.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
60	Alkem Laboratories Ltd.	Q V+ PT	67,124 Mid Cap	5,630.80 (0.30%)	30.72	4.8	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.75	3.26%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	590.30	2.17%
Laurus Labs	1,745.85	1.84%
Cipla	1,434.80	1.77%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,121.05	-7.35%
Senores Pharmaceutic	1,317.55	-6.66%
Suven Life Sciences	297.85	-4.44%
Wanbury	318.55	-3.82%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

SMS Pharmaceuticals informs about board meeting

SMS Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026, inter alia, to consider and approve Un-audited Financial Results of the Company for the first quarter ended on June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Dr. Lal Pathlabs - Quaterly Results

The company witnessed a 19.31% growth in the revenue at Rs. 7644.00 millions for the quarter ended June 2026 as compared to Rs. 6407.00 millions during the year-ago period.The company has announced a 28.31% increase in its profits to Rs . 1659.00 millions for the quarter ended June 2026 compared to Rs. 1293.00 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 2684.00 millions from 2097.00 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	7644.00	6407.00	19.31	7644.00	6407.00	19.31	26476.00	23516.00	12.59
Other Income	299.00	263.00	13.69	299.00	263.00	13.69	1127.00	1115.00	1.08
PBIDT	2684.00	2097.00	27.99	2684.00	2097.00	27.99	8664.00	7770.00	11.51
Interest	61.00	45.00	35.56	61.00	45.00	35.56	220.00	215.00	2.33
PBDT	2623.00	2052.00	27.83	2623.00	2052.00	27.83	8143.00	7555.00	7.78
Depreciation	400.00	328.00	21.95	400.00	328.00	21.95	1541.00	1342.00	14.83
PBT	2223.00	1724.00	28.94	2223.00	1724.00	28.94	6602.00	6213.00	6.26
TAX	564.00	431.00	30.86	564.00	431.00	30.86	1520.00	1240.00	22.58
Deferred Tax	-9.00	22.00	-140.91	-9.00	22.00	-140.91	14.00	-393.00	-103.56
PAT	1659.00	1293.00	28.31	1659.00	1293.00	28.31	5082.00	4973.00	2.19
Equity	1676.00	838.00	100.00	1676.00	838.00	100.00	1676.00	836.00	100.48
PBIDTM(%)	35.11	32.73	7.28	35.11	32.73	7.28	32.72	33.04	-0.96

Jul, 2026

Acutaas Chemicals - Quaterly Results

The Turnover for the quarter ended June 2026 of Rs. 3224.09 millions increase by 56.53% from Rs. 2059.71 millions.Net profit for the quarter ended June 2026 increased significantly by 70.00% to Rs. 758.96 millions from Rs. 446.46 millions.Operating profit for the quarter ended June 2026 rose to 1141.53 millions as compared to 670.09 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3224.09	2059.71	56.53	3224.09	2059.71	56.53	13237.92	9898.35	33.74
Other Income	44.76	160.20	-72.06	44.76	160.20	-72.06	458.78	183.36	150.21
PBIDT	1141.53	670.09	70.35	1141.53	670.09	70.35	5288.83	2434.78	117.22
Interest	11.18	6.20	80.32	11.18	6.20	80.32	30.77	58.57	-47.46
PBDT	1130.35	663.89	70.26	1130.35	663.89	70.26	5258.06	2376.21	121.28
Depreciation	90.20	74.62	20.88	90.20	74.62	20.88	330.32	240.45	37.38
PBT	1040.15	589.27	76.52	1040.15	589.27	76.52	4927.74	2135.76	130.73
TAX	281.19	142.81	96.90	281.19	142.81	96.90	1265.99	540.29	134.32
Deferred Tax	25.87	15.53	66.58	25.87	15.53	66.58	111.09	70.58	57.40
PAT	758.96	446.46	70.00	758.96	446.46	70.00	3661.75	1595.47	129.51
Equity	409.36	409.34	0.00	409.36	409.34	0.00	409.36	409.34	0.00
PBIDTM(%)	35.41	32.53	8.83	35.41	32.53	8.83	39.95	24.60	62.42

Jul, 2026

Akums Drugs’ arm gets nod to acquire Oriflame India’s manufacturing business

The said acquisition is expected to be completed by August 31, 2026

Jul, 2026

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition,’ which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Supriya Lifescience informs about newspaper advertisement

In terms of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that it enclosed copies of the newspaper advertisement extract for Postal Ballot Notice published in the newspapers, Financial Express (English Language) and Loksatta (Marathi Language).

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Max Healthcare Institute Ltd.	1,08,476 Crore
2	Yatharth Hospital & Trauma Care Services Ltd.	8,132 Crore
3	3B Blackbio Dx Ltd.	1,112 Crore
4	Artemis Medicare Services Ltd.	4,408 Crore
5	Novartis India Ltd.	4,023 Crore
6	Jupiter Life Line Hospitals Ltd.	10,728 Crore
7	Jagsonpal Pharmaceuticals Ltd.	1,511 Crore
8	Neuland Laboratories Ltd.	24,345 Crore
9	Kwality Pharmaceuticals Ltd.	2,815 Crore
10	Rainbow Childrens Medicare Ltd.	15,076 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,631	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,553	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,587	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,146	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,984	4,73,509	41.25	5.67	23.65	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

SMS Pharmaceuticals informs about board meeting

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Akums Drugs’ arm gets nod to acquire Oriflame India’s manufacturing business

Sun Pharmaceutical Industries informs about press release

Supriya Lifescience informs about newspaper advertisement

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.